Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer

NCT06686771 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT06686771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06686771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 3
Overall status
Recruiting
Start date
December 16, 2025
Completion date
December 31, 2030
Enrollment
320 (estimated)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer